# Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma

> **NCT00409214** · PHASE2 · COMPLETED · sponsor: **Light Sciences Oncology** · enrollment: 18 (estimated)

## Conditions studied

- Glioma
- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** LS11 (talaporfin sodium)
- **DEVICE:** Light source (interstitial light emitting diodes)
- **PROCEDURE:** Intraoperative placement of device in glioma

## Key facts

- **NCT ID:** NCT00409214
- **Lead sponsor:** Light Sciences Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2012-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00409214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00409214, "Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00409214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*